Empowered Funds LLC Invests $1.31 Million in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Empowered Funds LLC initiated a $1.31 million position in Alnylam Pharmaceuticals during the second quarter by purchasing 4,355 shares. Institutional investors collectively own 92.97% of the company.
• Analysts maintain a generally positive outlook, with Alnylam receiving a “Moderate Buy” consensus rating and an average price target of $386.14, despite several firms lowering their targets.
• Alnylam reported quarterly earnings of $1.84 per share, exceeding estimates of $1.63, while revenue rose 66.9% year over year to $1.29 billion, slightly below expectations.

Empowered Funds LLC purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 4,355 shares of the biopharmaceutical company's stock, valued at approximately $1,311,000.

Several other institutional investors have also recently bought and sold shares of the business. Daiwa Securities Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company's stock valued at $4,220,000 after buying an additional 35 shares in the last quarter. Golden State Wealth Management LLC grew its holdings in Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 36 shares during the last quarter. Coldstream Capital Management Inc. increased its position in Alnylam Pharmaceuticals by 2.4% in the 3rd quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company's stock valued at $748,000 after acquiring an additional 38 shares in the last quarter. Atlantic Union Bankshares Corp increased its position in Alnylam Pharmaceuticals by 20.9% in the 4th quarter. Atlantic Union Bankshares Corp now owns 231 shares of the biopharmaceutical company's stock valued at $92,000 after acquiring an additional 40 shares in the last quarter. Finally, Laird Norton Wetherby Wealth Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 3.3% in the third quarter. Laird Norton Wetherby Wealth Management LLC now owns 1,266 shares of the biopharmaceutical company's stock worth $577,000 after acquiring an additional 40 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

Analysts Set New Price Targets

Several research firms have issued reports on ALNY. Morgan Stanley reduced their price objective on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an "equal weight" rating on the stock in a report on Friday, July 31st. Needham & Company LLC lowered their target price on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a "buy" rating for the company in a research note on Thursday, July 30th. Chardan Capital reiterated a "buy" rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, July 31st. Sanford C. Bernstein reaffirmed a "buy" rating on shares of Alnylam Pharmaceuticals in a research note on Monday. Finally, HC Wainwright reiterated a "buy" rating and issued a $455.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $386.14.

Alnylam Pharmaceuticals Stock Up 0.6%

Alnylam Pharmaceuticals stock opened at $266.11 on Friday. The firm has a market cap of $35.61 billion, a price-to-earnings ratio of 49.46 and a beta of 0.31. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The firm has a 50 day moving average price of $259.25 and a two-hundred day moving average price of $291.61. Alnylam Pharmaceuticals, Inc. has a 52-week low of $197.81 and a 52-week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping analysts' consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The business had revenue of $1.29 billion during the quarter, compared to analysts' expectations of $1.32 billion. During the same period last year, the company posted ($0.51) earnings per share. The business's quarterly revenue was up 66.9% on a year-over-year basis. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source